Description: Patients with chronic conditions such as musculoskeletal pain, diabetes, and hypertension impact 50% of the US healthcare population, consume more than 85% of healthcare costs, and often require a higher volume of care, expensive imaging, testing, and emergency procedures, and long-term high-cost drugs. Managing these conditions through innovative digital health interventions provides a significant opportunity for higher-touch and more-effective management that will result in lower costs.

Description: It goes without saying that the analysis of data is a key aspect of actuarial practice, but do traditional actuarial approaches allow us to see the whole picture? Effective data analysis is also key to the identification of health disparities and measuring progress on health equity. Actuaries and others analyzing data for health equity purposes find themselves looking at data differently.

Description: In this session, we will review how the previous and current concerns of pharmacy actuaries will affect the forecasting and review of upcoming pipeline events. After this session, attendees will have a broader understanding of the implications of what is coming next in the pharmacy pipeline and how they can be thinking about it.

Description: This session will cover emerging topics in the individual disability insurance (IDI) market. These topics include a discussion of disabled life mortality and recovery experience, an update from the SOA Individual Disability Experience Committee, and a preliminary glimpse at 2023 IDI sales experience. Attendees will gain an understanding of the latest trends in this complex market.

Description: Every patient leaving the hospital has personal life-context circumstances that impact their chances of successful recovery and complications can be costly. Complex care management impacts over 50 percent of health care spend, with the admitted commercial population driving 37 percent of spend or $177M per 100,000 lives and the Medicare population driving 53 percent of spend or $600 million per 100,000 lives. The stakes are high, but existing care management solutions are mostly clinical and navigation call centers provide fragmented and outdated patient management systems, and do not address individual life-context. Discharged patients therefore remain underengaged and undercompliant, leading to costly complications. Innovative technology can help enable and integrate systems and existing infrastructure to leverage evidence-based contextualized care that will enhance care management, improve efficiency, and drive a better experience and outcomes for patients. This technology helps codifies life context, dynamically stratifying and engaging members digitally and telephonically helping virtual care teams to be more effective and efficient. In a recent randomized clinical trial, this technology and approach has shown a 50 percent reduction in the total cost of care, cutting the average and total cost of readmission, increasing virtual care team impact and member engagement and trust.

Description: Explore historical trends in enrollment, carrier participation, and competition over the first 10 years of the individual marketplace as a basis to frame what the future could hold for the next 10 years. Draw parallels to other lines of business (e.g., Medicare Advantage, employer group) as we look at how the market may evolve and the capabilities required to succeed. This session would be valuable for anyone interested in consumer purchasing behavior, quality and risk adjustment, employer benefits, provider dynamics, and the individual market more broadly. By attending this this session, you will be able to articulate the impact of recent legislation and regulatory actions on the Individual market, including subsidies, employer funding vehicles (e.g., ICHRA), distribution channels, and product requirements.

Description: As more gene and cell therapies enter the market at increasingly higher price points, they are ushering in a new era of medicine for rare diseases. Unlike most traditional therapies, gene and cell therapies typically have a short or one-time treatment administration and are anticipated to provide long-term clinical benefits. Actuaries must be prepared to assess, manage, and/or mitigate the risks associated with these therapies. This session includes three different perspectives—a regional plan, a stop loss/reinsurance carrier, and a health care consultant.

Description: With record numbers of job openings, rising interest rates, the highest inflation in decades, and the possibility of a recession, it has been an unusual and challenging time for the U.S. economy. Explore the impact that recent economic trends may have on group disability insurance, including morbidity, growth, and financial performance..

Description: Discover the multitude of risk transfer solutions and payment models available to health claims payers for cell & gene therapies in this Society of Actuaries webinar. Delving deeper into the topic, we will examine the different types of solutions, weigh their pros and cons, and explore the future prospects of this rapidly evolving area of the healthcare landscape. By expanding upon the pricing and risk exposure discussion from session two, this webinar provides valuable insights into the dynamic market for cell & gene therapies and its implications for actuaries.

Description: Actuarial Standards of Practice (ASOPs) are critical to an actuary's work, but staying abreast of changes to ASOPs could be challenging. Several ASOPs have been created or updated in the last few years while ValAct was on hiatus. Are you up to date? This session will focus on ASOPs 7, 11, 28, 41 and 57. Come ready to play, as we challenge your knowledge of these ASOPs in a fun game show format. By the end of this session, attendees will learn the major provisions included in ASOPs that have been recently updated or created and understand how their work may be impacted by these recent changes.